With little explanation for why Merck’s potential Covid-19 antiviral was less effective in reducing Covid hospitalizations and deaths in a full analysis of a Phase III trial versus an interim look,…
Drug developers at Gilead Sciences are moonlighting as college professors these days. However, it’s not a side hustle for extra income, but a new program to help draw Black and Hispanic students to…
Barely a month after disappointing data shattered hopes for a major label expansion for the GI tumor drug Qinlock, Deciphera is making a major pivot — scrapping development plans for that drug and…
Jeff Dachis knows how to pick a business wave — although it may be more accurate to say he knows how to create them. The founder and CEO of digital health platform One Drop is working to transform the…
GlaxoSmithKline has appointed Philip Dormitzer, formerly chief scientific officer of Pfizer’s viral vaccines unit, as its newest global head of vaccines R&D, looking to leverage one of the leading…
Since our start in 2016, Endpoints has grown fast while executing our mission to cover biopharma’s most critical developments for industry pros worldwide. As readership has grown, our advertising…
Younger teens could be eligible for the Pfizer-BioNTech Covid-19 booster shots as early as next week, the Wall Street Journal reported Monday. The companies will apply for regulatory approval for a…
Thanks in part to interest from Big Pharma players like Bayer and Novartis over the last decade, there’s been no shortage in cash for new companies looking to slay tumor cells with targeted…
The former Fierce 15 winner announced that the first healthy volunteer in an Australian study has received a limited, intravenous dose of the company’s ISM001-055, a small-molecule inhibitor aimed at…
GlaxoSmithKline has seen a host of vaccine research staffers exit the Big Pharma over the past year, but it’s hoping a big name can get its vaccine business back on track.
